Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Head and Neck Cancer

Free Subscription Articles published in Am J Surg Retrieve available abstracts of 50 articles: HTML format

Single Articles

July 2026
1. GHANI A, Al Darwashi LM, Hajeir MY, Hunter NK, et al
   Comparative safety of completion thyroidectomy following lobectomy versus total thyroidectomy in differentiated thyroid cancer: A systematic review and meta-analysis.
   Am J Surg. 2026;257:116977.
   PubMed     Abstract available
   
   
   June 2026
2. MILAN M, Thomas SM, Terry J, Frieze TW, et al
   Should patient age be incorporated into Oncocytic thyroid carcinoma staging? Evidence from SEER and NCDB.
   Am J Surg. 2026;260:117105.
   PubMed     Abstract available
   
   
   March 2026
3. THORNTON A, Kuo E, Lee J, Hu Y, et al
   Radiofrequency ablation for nodal recurrence in papillary thyroid carcinoma.
   Am J Surg. 2026;256:116920.
   PubMed     Abstract available
   
   
   
4. JENSEN CB, Xie S, Sinha A, Bacon EM, et al
   Statewide episode spending variation of thyroidectomy for lower-risk thyroid cancer.
   Am J Surg. 2026;253:116816.
   PubMed     Abstract available
   
   
   February 2026
5. MILAN M, Thomas SM, Lindsay CV, Frieze TW, et al
   Data-driven thresholds for tumor size and nodal involvement in oncocytic thyroid carcinoma: A population-based analysis.
   Am J Surg. 2026;255:116874.
   PubMed     Abstract available
   
   
   
6. ROGERS JL, Henostroza S, Fahey A, Solorzano CC, et al
   Cost analysis in thyroid cancer clinical trials: Toward value-based oncology care.
   Am J Surg. 2026;252:116772.
   PubMed     Abstract available
   
   
   
7. SWAMINATHAN N, Song Z, Wu C, Akhund R, et al
   Diagnostic value of molecular testing for evaluating thyroid nodules greater than 4 centimeters.
   Am J Surg. 2026;252:116755.
   PubMed     Abstract available
   
   
   
8. LYON S, Turza A, Ganesan S, McHenry CR, et al
   Positive predictive value of the Afirma gene sequencing classifier for evaluation of the indeterminate thyroid nodule: An institutional experience.
   Am J Surg. 2026;252:116759.
   PubMed     Abstract available
   
   
   
9. MONTGOMERY KB, Rademacher N, Richman JS, Bhatia S, et al
   Healthcare facility volume and evidence-based practice implementation in surgical care of patients with common cancers.
   Am J Surg. 2026;252:116733.
   PubMed     Abstract available
   
   
   December 2025
10. ABRAHAM P, Dream S
    Pushing the Envelope: Expanding the use of thermal ablative techniques for small papillary thyroid carcinomas.
    Am J Surg. 2025 Dec 15:116780. doi: 10.1016/j.amjsurg.2025.116780.
    PubMed    
    
    
    
11. SONG Z, Akund R, Wu C, Fazendin J, et al
    Performance of molecular testing for indeterminate thyroid nodules in Black patients.
    Am J Surg. 2025;250:116569.
    PubMed     Abstract available
    
    
    
12. LUI MS, Hangge PT, DeLozier O, Patel KN, et al
    More than just stuck in the middle: papillary thyroid cancer of the isthmus may present with aggressive features and nodal metasasis.
    Am J Surg. 2025;250:116621.
    PubMed     Abstract available
    
    
    November 2025
13. FUNG MHM, Ng WI, Lee HE, Chan TH, et al
    The role of artificial intelligence in surgeon-performed ultrasonographic evaluation of cytologically indeterminate thyroid nodules.
    Am J Surg. 2025;249:116599.
    PubMed     Abstract available
    
    
    October 2025
14. LIOU R, Slattery L, Hu Y, Kuo EJ, et al
    Short-term outcomes in radiofrequency ablation for the primary treatment of T1N0M0 papillary thyroid carcinomas.
    Am J Surg. 2025 Oct 31:116702. doi: 10.1016/j.amjsurg.2025.116702.
    PubMed     Abstract available
    
    
    
15. PATEL H, Somasundar P, Espat NJ, Calvino AS, et al
    Defining the role of thyroidectomy in patients with metastatic differentiated thyroid carcinoma by age groups.
    Am J Surg. 2025;250:116660.
    PubMed     Abstract available
    
    
    
16. ZHANG G, Chen Y, Jin D, Sui Z, et al
    Postoperative survival evaluation of patients with Siewert II adenocarcinoma of esophagogastric junction: a population-based study.
    Am J Surg. 2025;248:116536.
    PubMed     Abstract available
    
    
    
17. DONE JZ, Helbing A, Stemme R, Foote D, et al
    Higher Distressed Communities Index is associated with more aggressive features in papillary thyroid cancer.
    Am J Surg. 2025;248:116520.
    PubMed     Abstract available
    
    
    
18. MONREAL AJ, Eze AN, Thomas SM, Johnson KS, et al
    Exploring actionable targets to address disparities in thyroid cancer survival: A study of patients with aggressive variants of papillary thyroid cancer.
    Am J Surg. 2025;248:116428.
    PubMed     Abstract available
    
    
    
19. LAURIE BD, Thomas E, Nguyen H, Ryan S, et al
    FDG-avid thyroid nodules are at a significantly increased risk of malignancy.
    Am J Surg. 2025;248:116400.
    PubMed     Abstract available
    
    
    September 2025
20. FINNERTY BM, Marshall T, Annesi CA, Zarnegar R, et al
    Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves' disease and papillary thyroid cancer.
    Am J Surg. 2025;247:116487.
    PubMed     Abstract available
    
    
    
21. AKINYEMI O, Weldeslase T, Fasokun M, Eze O, et al
    Medicaid expansion and thyroid cancer stage at presentation: A comparative study of two US states.
    Am J Surg. 2025;247:116447.
    PubMed     Abstract available
    
    
    August 2025
22. DING Y, Feng Z, Cao K
    Total thyroidectomy does not improve survival for all patients with unilateral papillary thyroid cancer exceeding 4 ?cm.
    Am J Surg. 2025;246:116395.
    PubMed     Abstract available
    
    
    May 2025
23. AMERI K, Kwon M, Watanabe A, Wiseman SM, et al
    Thyroid cancer quality of care indicators: A scoping review.
    Am J Surg. 2025;243:116223.
    PubMed     Abstract available
    
    
    March 2025
24. RAMESH S, Fisher JC, Curcio P, Rothberger GD, et al
    Malignancy risk associated with radioactive iodine therapy for Graves' disease.
    Am J Surg. 2025;241:116075.
    PubMed     Abstract available
    
    
    
25. RYU YJ, Hsu SY, Kuo EJ, Liou R, et al
    Radiofrequency ablation of Bethesda category III thyroid nodules with benign molecular testing: Preliminary findings from a single institution.
    Am J Surg. 2025;241:115929.
    PubMed     Abstract available
    
    
    February 2025
26. ZMIJEWSKI P, Nwaiwu C, Nakanishi H, Farsi S, et al
    Racial disparities in thyroid cancer outcomes: A systematic review.
    Am J Surg. 2025;240:115991.
    PubMed     Abstract available
    
    
    January 2025
27. BARRIO MJ, Pozdeyev N, McIntyre RC Jr, Albuja-Cruz MB, et al
    Long term outcomes after repeat lymph node dissections for persistent or recurrent differentiated thyroid cancer.
    Am J Surg. 2025;239:116045.
    PubMed     Abstract available
    
    
    December 2024
28. MARSHALL TE, Ibrahim R, Lee-Saxton YJ, Tumati A, et al
    Disparities in postoperative adjuvant therapy utilization and factors impacting survival among anaplastic thyroid cancer patients.
    Am J Surg. 2024;238:115944.
    PubMed     Abstract available
    
    
    
29. COGUA LM, Tupper CJ, Silberstein PT, Coan KE, et al
    Intermediate-sized follicular thyroid cancer surgical trends before and after the 2015 American thyroid association guideline changes.
    Am J Surg. 2024;238:115830.
    PubMed     Abstract available
    
    
    
30. BARRIO MJ, Pozdeyev N, Raeburn CD, McIntyre RC Jr, et al
    Pre-operative thyroglobulin measurement for thyroid cancer risk of recurrence and response to therapy.
    Am J Surg. 2024;238:115818.
    PubMed     Abstract available
    
    
    November 2024
31. CHAN SJ, Betcher MC, Kuo EJ, McManus CM, et al
    Trends in thyroid function following radiofrequency ablation of benign, nonfunctioning thyroid nodules: A single institution review.
    Am J Surg. 2024;237:115793.
    PubMed     Abstract available
    
    
    October 2024
32. ROSSI L, De Palma A, Ambrosini CE, Fregoli L, et al
    Histologic parameters driving completion thyroidectomy for papillary thyroid carcinoma in a high-volume institution: A retrospective observational study.
    Am J Surg. 2024;239:116016.
    PubMed     Abstract available
    
    
    August 2024
33. SU MW, Beck TN, Knepprath J, Romero-Velez G, et al
    Primary thyroid lymphoma: A multi-center retrospective review.
    Am J Surg. 2024;237:115927.
    PubMed     Abstract available
    
    
    
34. MONREAL A, Eze AN, Kazaure HS
    Presentation and management of medullary thyroid cancer by sex and race/ethnicity in the United States-A state of disunion.
    Am J Surg. 2024;234:17-18.
    PubMed    
    
    
    
35. GILLIS A, Zmijewski P, Mcleod MC, Lindeman B, et al
    Racial implications of time to surgery in disparities in thyroid cancer survival.
    Am J Surg. 2024;234:85-91.
    PubMed     Abstract available
    
    
    
36. KALVA S, Ginzberg SP, Passman JE, Soegaard Ballester JM, et al
    Sex differences and racial/ethnic disparities in the presentation and treatment of medullary thyroid cancer.
    Am J Surg. 2024;234:19-25.
    PubMed     Abstract available
    
    
    July 2024
37. BROEKHUIS JM, Gartland RM
    More than meets the size: Evaluating guideline impact on extent of surgery for follicular thyroid carcinoma.
    Am J Surg. 2024 Jul 26:115863. doi: 10.1016/j.amjsurg.2024.115863.
    PubMed    
    
    
    
38. ABRAHAM PJ, Wu C, Wang R, Herring B, et al
    The overtreatment of papillary thyroid microcarcinoma in the community.
    Am J Surg. 2024;233:132-135.
    PubMed     Abstract available
    
    
    
39. BECK TN, Romero-Velez G, Noureldine SI, Plitt G, et al
    Bilateral exploration in primary hyperparathyroidism: Double adenoma distribution and biochemical patterns over two decades.
    Am J Surg. 2024;233:61-64.
    PubMed     Abstract available
    
    
    June 2024
40. LI R, Luo Q, Gutierrez ID
    Asian Americans have higher 30-day surgical complications after esophagectomy: A propensity-score matched study from ACS-NSQIP database.
    Am J Surg. 2024;232:75-80.
    PubMed     Abstract available
    
    
    April 2024
41. NABATA KJ, Lim R, Leong R, Wiseman SM, et al
    To infinity and beyond: A historical bibliometric analysis of medullary thyroid carcinoma.
    Am J Surg. 2024 Apr 15:S0002-9610(24)00199-5. doi: 10.1016/j.amjsurg.2024.
    PubMed     Abstract available
    
    
    March 2024
42. LEONG D, Leslie C, Laurie B, Hou L, et al
    Tumour size predicts risk of recurrence in tall cell subtype papillary thyroid carcinoma.
    Am J Surg. 2024 Mar 26:S0002-9610(24)00184-3. doi: 10.1016/j.amjsurg.2024.
    PubMed     Abstract available
    
    
    
43. INNES AM, van Galen P
    Insights from the hereditary endocrine clinic.
    Am J Surg. 2024;229:203-204.
    PubMed    
    
    
    
44. HERRERA M, Hussein MH, Persons E, Alias MR, et al
    Survival benefits of extensive surgery in patients with papillary thyroid microcarcinoma.
    Am J Surg. 2024;229:99-105.
    PubMed     Abstract available
    
    
    
45. TRAN A, Weigel RJ, Beck AC
    ATA risk stratification in papillary thyroid microcarcinoma has low positive predictive value when identifying recurrence.
    Am J Surg. 2024;229:106-110.
    PubMed     Abstract available
    
    
    February 2024
46. SMITH ER, Frye CC, Pandian TK, Gillanders WE, et al
    Molecular characteristics of isthmus papillary thyroid cancers: Supporting evidence for unfavorable clinical behavior.
    Am J Surg. 2024;228:146-150.
    PubMed     Abstract available
    
    
    
47. MONTGOMERY KB, Fazendin JM, Chen H, Broman KK, et al
    Contemporary trends in extent of surgery for differentiated thyroid cancer with extrathyroidal extension.
    Am J Surg. 2024;228:173-179.
    PubMed     Abstract available
    
    
    August 2023
48. KUO LE, Suh I
    Can we improve preoperative staging for thyroid cancer?
    Am J Surg. 2023;226:170.
    PubMed    
    
    
    
49. K SAH R, Mayilvaganan S
    "Primary hyperparathyroidism after radioactive iodine therapy. Is it a distinct clinical entity?".
    Am J Surg. 2023;226:296.
    PubMed    
    
    
    
50. SOEGAARD BALLESTER JM, Finn CB, Ginzberg SP, Kelz RR, et al
    Thyroid cancer pathologic upstaging: Frequency and related factors.
    Am J Surg. 2023;226:171-175.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum